Molla Imaduddin Ahmed, ERS 2021: Tezacaftor/Ivacaftor Effect on Exercise Capacity in Adolescents with Cystic Fibrosis

It was a pleasure to speak with Dr Molla Imaduddin Ahmed (Leicester Childrens’ Hospital, Leicester, UK) around his abstract on ‘The impact of Symkevi (Tezacaftor/Ivacaftor) on exercise capacity in adolescents with CF.‘, which was presented at ERS International Congress 2021, 5-8 September 2021.

Questions

1. How useful is exercise capacity as a clinical endpoint for cystic fibrosis (CF)? (0:20)
2. What were the aims and design of your recent study of Tezacaftor/Ivacaftor on exercise capacity in adolescents with CF? (1:50)
3. What were the findings of this study? (2:52)
4. What are the implications of these findings in terms of future clinical trial design? (4:33)

Disclosures: Molla Imaduddin Ahmed has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of ERS 2021 (Virtual).